BridgeMD
New treatment option for Primary Liver Cancer
Official title The Dragon PLC Trial (DRAGON-PLC)
ClinicalTrials.gov ID: NCT06914648
What this study is testing
- What it's testing
- The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- PLC diagnosis, specifically iCCC, pCCC, and HCC;
- Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from...
- Age ≥ 18 years;
- Able to understand the trial and provide informed consent.
You likely can't join if
- Liver cirrhosis with a Child-Pugh score of B or C;
- Presence of portal hypertension;
- Presence of cholangitis;
- Pregnant women;
- Premenopausal females not able/willing to commit to contraception (specifically long-acting reversible contraception or hormonal contraception);
- Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team);
See the full eligibility criteria
- PLC diagnosis, specifically iCCC, pCCC, and HCC;
- Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization /...
- Age ≥ 18 years;
- Able to understand the trial and provide informed consent.
- Liver cirrhosis with a Child-Pugh score of B or C;
- Presence of portal hypertension;
- Presence of cholangitis;
- Pregnant women;
- Premenopausal females not able/willing to commit to contraception (specifically long-acting reversible contraception or hormonal contraception);
- Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team);
- Patients with hepatic malignancies other than iCCC, pCCC or HCC;
- PVE/HVE anatomically not feasible;
- Any patient with non-resectable or non-ablatable extrahepatic metastatic disease.
- Unable to understand the study information, study instructions and give informed consent
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
- Chicago, Illinois, United States
- Rochester, Minnesota, United States
- New York, New York, United States
- Cleveland, Ohio, United States
- Melbourne, Australia
- Vienna, State of Vienna, Austria
- Brussels, Brussels Capital, Belgium
- Antwerp, Edegem, Belgium
- Ghent, Gent, Belgium
- Liège, Liège, Belgium
- Yvoir, Namen, Belgium
- Brussels, Belgium
- Hasselt, Belgium
- Jette, Belgium
- Kortrijk, Belgium
- Calgary, Alberta, Canada
- Vancouver, British Columbia, Canada
- Halifax, Nova Scotia, Canada
- Hamilton, Ontario, Canada
+ 30 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States; Chicago, Illinois, United States; Rochester, Minnesota, United States; New York, New York, United States; Cleveland, Ohio, United States; Melbourne, Australia and 44 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.